SCHEMBL6728569

SCHEMBL6728569

Cc1cc(COc2cc(-c3ccc([N+](=O)[O-])cc3)nc(-c3ccccc3)n2)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 1/20 0.47
MAPT P10636 4/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
EIF4A1 P60842 3/20 0.42
GSTP1 P09211 1/20 0.42
MCL1 Q07820 1/20 0.42
VCP P55072 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 2/20 0.40
MAPK1 P28482 1/20 0.40
MAOB P27338 2/20 0.40
RXRA P19793 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
PLA2G4B P0C869 1/20 0.40
MAOA P21397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6728046 0.86 ALDH1A1 (0.46) LTB4RMAPTALDH1A1MEN1KMT2A
SCHEMBL6728566 0.85 MAPT (0.52) LTB4RMAPTALDH1A1MEN1KMT2A
SCHEMBL4804158 0.77 RXRA (0.53) MEN1KMT2ASMN1; SMN2MCL1VCP
SCHEMBL4802532 0.73 CTRC (0.55) LTB4RMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL28489642 0.73 MEN1 (0.60) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL6731942 0.73 MEN1 (0.60) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL4807278 0.72 RXRA (0.48) SMN1; SMN2MCL1VCPMAPK1RXRA
SCHEMBL6728049 0.70 MEN1 (0.48) LTB4RMAPTALDH1A1MEN1KMT2A
SCHEMBL14987897 0.70 MAPK1 (0.68) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL1761421 0.69 TDP1 (0.53) MAPTALDH1A1KMT2APOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis ARRHENIUS THOMAS (US) 2004-06-10 US disclosed
EP-1370250-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP disclosed
WO-2002076438-A2 FLT-1 LIGANDS AND THEIR USES IN THE TREATMENT OF DISEASES REGULATABLE BY ANGIOGENESIS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110757-A1 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis FLT1, FLT4, TEK LTB4R 677/4885MAPT 2310/4885ALDH1A1 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.